Ticker | Company Name | Drug Name | Indication | NCT | Next Catalyst | Stage | FDA Status | Catalyst Date | Conference | Market Cap | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
A ACHV | Achieve Life Sciences Inc. | Cytisinicline - (ORCA-3) | Smoking cessation of cigarettes | PDUFA | Ongoing | 2026-06-20 | $154.4M | $16.0M | |||
M MNMD | Mind Medicine (MindMed) Inc. | MM120 (lysergide D-tartrate, LSD) - (Voyage) | Generalized Anxiety Disorder (GAD) | NCT05407064 | Topline Data | Phase 3 | Ongoing | 2026-06-30 | $1.5B | $3.8M | |
A ARTV | Artiva Biotherapeutics Inc. | AlloNK (B-101) with rituximab | Refractory rheumatoid arthritis (RA) | Initial Data | Phase 1 | Ongoing | 2026-06-30 | $129.3M | $100.3M | ||
A ALXO | ALX Oncology Holdings Inc. | ALX2004 | Solid Tumors | Initial Data | Phase 1 | Ongoing | 2026-06-30 | $268.5M | $353.9K | ||
M MIRM | Mirum Pharmaceuticals Inc. | Volixibat - (VISTAS) | Primary sclerosing cholangitis | NCT04663308 | Topline Data | Phase 2b | Data Released | 2026-06-30 | $5.3B | $351.1K | |
M MLTX | MoonLake Immunotherapeutics | Nanobody sonelokimab - (IZAR) | Active psoriatic arthritis (PsA) | NCT05640245 | Initial Data | Phase 3 | Enrollment Initiation | 2026-06-30 | $1.4B | $4.5M | |
C CNTX | Context Therapeutics Inc. | CTIM-76 | Various cancers | Initial Data | Phase 1 | Enrollment Initiation | 2026-06-30 | $292.2M | $659.7K | ||
A ALLO | Allogene Therapeutics Inc. | ALLO-329 - (RESOLUTION) | Autoimmune Disease (AID) | Initial Data | Phase 1 | Ongoing | 2026-06-30 | $538.7M | $2.6M | ||
A ARGX | argenx SE | ARGX-213 - (FcRn) | Inflammation | Initial Data | Phase 1 | Ongoing | 2026-06-30 | $42.0B | $452.5K | ||
A AMLX | Amylyx Pharmaceuticals Inc. | Avexitide (Exendin 9-39) - (LUCIDITY) | Post-Bariatric Hypoglycemia (PBH) | NCT03373435 | Initial Data | Phase 3 | Ongoing | 2026-06-30 | $1.5B | $1.9M |
Rows per page
Page 1 of 30